Clinical trial

Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung Cancer

NCT00276276

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2000-11-01

PhasePHASE3

Study timeline

Study start (unknown)2000-11-01Date precision: month

Registry last updated2013-04-15

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Lung Cancer, Small Cellunresolved

Interventions

topotecanDRUG · verified · RxNorm: topotecan

Sponsors & collaborators

GlaxoSmithKlinelead sponsor

Mapped research locations

BudapestHungary3 MoscowRussia1 PlovdivBulgaria1 LvivUkraine1 PlevenBulgaria1 VarnaBulgaria1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00276276 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.